Cholesterol Awareness – What Your Yearly Cholesterol Check Isn’t Telling You
Heart disease is the number one killer in America, yet the vast majority of cases can be prevented when screening and treatment match modern standards. Here’s what a deeper look at your heart health really involves.
Heart disease is the leading cause of death in the United States, yet almost all of it is preventable. When we screen early, look deeper than a single cholesterol number, and treat risk aggressively before symptoms appear, the majority of heart attacks and strokes simply don’t have to happen.
Everyday primary care often falls short of that standard. You get your LDL, your doctor recommends a statin or tells you to eat more fish, and that’s the extent of the conversation. But has anyone ever explained your actual risk of a heart attack or stroke, where it comes from, and what can be done about it?
Statins are valuable, and we prescribe them when they fit. But reaching for a statin reflexively, or waving cholesterol off as a lifestyle problem, both miss the mark. Modern cardiovascular prevention has a wider toolbox than most patients realize, and using it well starts with knowing your actual risk with both lab work and imaging.
The science is changing, fast.
In March 2026, the American College of Cardiology, the American Heart Association, and nine other leading medical organizations released a sweeping update to the national cholesterol guidelines, the first major overhaul since 2018. The message is clear: cardiovascular risk hasn’t been treated aggressively enough, and screening needs to start earlier in life. One practical shift is the return of clear cholesterol targets, giving patients and doctors concrete goals based on individual risk.
The test almost no one has had.
For the first time in a U.S. guideline, every adult is now advised to have their lipoprotein(a), or Lp(a), measured at least once in their lifetime. Lp(a) is a form of cholesterol you inherit from your parents, and a standard lipid panel doesn’t detect it. If your level is high, your risk of heart attack and stroke climbs independently of your LDL, the “bad cholesterol” most people know. Because it’s genetic and stays steady through life, a single test can reveal something you may never have known.
The new guidelines also set tougher goals for the highest risk patients. For people with established heart disease, the LDL goal is now below 55 mg/dL, meaningfully more aggressive than the target many patients are currently treated to. The guiding principle, in the words of the writing committee: lower, and for longer, is better.
Cholesterol is only part of the story.
A cholesterol number tells you about risk factors. It doesn’t tell you whether disease is already there. That’s where imaging and advanced testing come in, and they change what we recommend.
A coronary calcium score is a quick, low-radiation CT scan that directly measures calcified plaque in the arteries of the heart. The new guidelines now suggest it for men over 40 and women over 45. A score of zero in a middle-aged patient with borderline cholesterol may reasonably shift the plan toward lifestyle and close monitoring rather than medication. A high score in someone whose “cholesterol looked fine” means the disease is already underway and treatment needs to be more aggressive than the lab report alone would suggest.
When more detail is needed, coronary CT angiography goes a step further. Using contrast dye, it visualizes the arteries themselves and detects soft, non-calcified plaque that a calcium score can miss, along with any narrowing that may already be limiting blood flow. It turns a risk estimate into a direct look at the disease.
Advanced lipid testing does similar work from a different angle. ApoB counts the actual number of cholesterol-carrying particles rather than the cholesterol they contain, and it predicts risk better than LDL. Add inflammation markers, and the picture sharpens considerably. Tools like the American Heart Association’s PREVENT equations then pull these inputs together into a long-term risk estimate more accurate than older calculators. By the time a heart attack or stroke happens, the disease has often been building quietly for decades. This is how you find it early.
More than one tool in the toolbox.
Once your true risk is clear, treatment can be tailored to it. For patients who don’t tolerate statins, don’t want them, or need additional LDL lowering, the options have expanded dramatically. PCSK9 inhibitors like evolocumab (Repatha) and alirocumab (Praluent) are injectable medications that can drop LDL by 50 to 60 percent and are the only agents currently shown to meaningfully lower Lp(a). Bempedoic acid (Nexletol) is an oral non-statin that reduces cardiovascular events. Ezetimibe adds another layer of LDL reduction with decades of safety behind it.
The right plan is the one matched to your biology, your risk, and your preferences. Behind all of it sit the lifestyle levers that remain the most powerful tools we have: nutrition, sleep, strength training, and stress recovery.
A plan built around you.
Your primary care doctor should be staying current with the evolving research and building a personalized risk-reduction strategy with you, not just tracking your LDL and HDL year to year. The goal isn’t a lipid panel that looks normal on paper. The goal is to make sure you never become the patient with chest pain in an emergency room.
Ask your doctor: “Have I ever had my Lp(a) checked, and do I know my real cardiovascular risk, not just my cholesterol number?” It’s a simple question that could change everything.
Joseph Sharp, MD, and Talley Sharp, MD, are board-certified physicians and co-founders of Sharp Health MD, a concierge primary care practice in Naples focused on prevention and longevity.
Dr. Joey Sharp
Board-Certified
Internal Medicine
Dr. Talley Sharp
Board-Certified
Emergency Medicine
